Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10591333 | Bioorganic & Medicinal Chemistry Letters | 2013 | 8 Pages |
Abstract
γ-Secretase modulators (GSMs) are potentially disease-modifying treatments for Alzheimer's disease. They selectively lower pathogenic Aβ42 levels by shifting the enzyme cleavage sites without inhibiting γ-secretase activity, possibly avoiding known adverse effects observed with complete inhibition of the enzyme complex. A cell-based HTS effort identified the sulfonamide 1 as a GSM lead. Lead optimization studies identified compound 25 with improved cell potency, PKDM properties, and it lowered Aβ42 levels in the cerebrospinal fluid (CSF) of Sprague-Dawley rats following oral administration. Further optimization of 25 to improve cellular potency is described.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jian Jeffrey Chen, Wenyuan Qian, Kaustav Biswas, Chester Yuan, Albert Amegadzie, Qingyian Liu, Thomas Nixey, Joe Zhu, Mqhele Ncube, Robert M. Rzasa, Frank Jr., Ning Chen, Frenel DeMorin, Shannon Rumfelt, Christopher M. Tegley, Jennifer R. Allen,